Results 191 to 200 of about 48,910 (280)

Serum Villin‐1—A Novel Marker of Gut Barrier Damage in Acutely Decompensated Cirrhosis: A Cohort Study and Validation

open access: yesAlimentary Pharmacology &Therapeutics, EarlyView.
Serum villin‐1 is a non‐invasive indicator of gut barrier damage and short‐term mortality in acutely decompensated cirrhosis. Incorporating villin‐1 assessment into risk stratification methods improves prognostic accuracy by capturing an essential, yet previously overlooked component of disease progression.
David Tornai   +22 more
wiley   +1 more source

Dual Use Research of Concern—The Necessity of Global Bioethics Engagement

open access: yesBioethics, EarlyView.
ABSTRACT Dual use research of concern (DURC) refers to research conducted for legitimate scientific purposes that could also be misused to pose a significant threat to public health and safety, agricultural crops and other plants, animals, the environment, or national security.
Daniel J. Hurst, Christopher A. Bobier
wiley   +1 more source

<i>In Vivo</i> Multicellular Feedback Control in Synthetic Microbial Consortia. [PDF]

open access: yesACS Synth Biol
Salzano D   +5 more
europepmc   +1 more source

Bacteria produce and use redox mediators for electron transfer in microbial fuel cells [PDF]

open access: yes, 2004
Boon, Nico   +5 more
core  

Artificial intelligence streamlines scientific discovery of drug–target interactions

open access: yesBritish Journal of Pharmacology, EarlyView.
Abstract Drug discovery is a complicated process through which new therapeutics are identified to prevent and treat specific diseases. Identification of drug–target interactions (DTIs) stands as a pivotal aspect within the realm of drug discovery and development. The traditional process of drug discovery, especially identification of DTIs, is marked by
Yuxin Yang, Feixiong Cheng
wiley   +1 more source

Rationale and design of a parallel randomised trial of a plant‐based intensive lifestyle intervention for diabetes remission: The REmission of diabetes using a PlAnt‐based weight loss InteRvention (REPAIR) trial

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
Abstract Aims As type 2 diabetes (T2D) continues to rise globally and remains a major driver of cardiovascular disease, its remission has emerged as a therapeutic target. Current evidence supports bariatric surgery and low‐calorie diets with meal replacements.
Brighid McKay   +19 more
wiley   +1 more source

Home - About - Disclaimer - Privacy